FDA Approves ZIEXTENZO — Sandoz Inc

Sandoz Inc. has secured FDA approval for the biosimilar PEGFILGRASTIM-BMEZ (ZIEXTENZO), filling a major void in the market for a subcutaneous granulocyte colony-stimulating factor (G-CSF) alternative by leveraging Peplin's manufacturing technology. This approval is expected to invigorate competition in the oncology market, offering healthcare providers a cost-effective option in the wake of the anticipated expiration of key Amgen patents for Neulasta.